Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
• To evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through one year post-transplant. • To evaluate the safety of ASP0113 in subjects undergoing allogeneic HCT
Inclusion criteria
- CMV reactivation after allogeneic stem cell transplantation